Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 97, 70-76
Abstract
No abstract availableKeywords
Funding Information
- Orionis Biosciences NV
- UGent Methusalem and Advanced ERC (340941)
- Labex MAbImprove
- Institut Carnot CALYM
- Institut National Du Cancer
- Orionis Biosciences
This publication has 48 references indexed in Scilit:
- Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosisNeuropsychiatric Disease and Treatment, 2013
- Compensatory dendritic cell development mediated by BATF–IRF interactionsNature, 2012
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)British Journal of Pharmacology, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancementBlood, 2008
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectinJournal of Clinical Investigation, 2008
- An Engineered Second Disulfide Bond Restricts Lymphotactin/XCL1 to a Chemokine-like Conformation with XCR1 Agonist ActivityBiochemistry, 2007
- Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursorsBlood, 2006